Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. …
この記事を読む
「論文メモ」の記事一覧 11ページ
この記事を読む
IMpower 150のEGFR遺伝子変異陽性群についてのupdate
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups …
この記事を読む
ロルラチニブのbeyond投与
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. Ou SI et al.J Thorac Oncol. 2022 Apr;17(4):…
この記事を読む
間質性肺炎合併肺癌の手術成績
Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia. Fukui M et al.Lung C…
この記事を読む
定位放射線治療での予後予測
Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung C…
この記事を読む
RECIST評価 大きいもの2病変で十分？
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cance…
この記事を読む
コロナ感染者にワクチンの意味はあるか？
Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. Hammerman A et al.N Engl J Med. 2022 Feb 16 Epub ahe…
この記事を読む
ペメトレキセド維持療法の投与間隔を延ばしても予後に悪影響を与えない？
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experie…
この記事を読む
KRASと併存するSTK11とKEAP1変異の免疫療法における意味
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected …
この記事を読む
術後補助化学療法の維持療法；IMpower010
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a r…